X4 Pharmaceuticals Inc (NASDAQ: XFOR) kicked off on Tuesday, down -0.50% from the previous trading day, before settling in for the closing price of $0.50. Over the past 52 weeks, XFOR has traded in a range of $0.47-$1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -20.00%. While this was happening, its average annual earnings per share was recorded 80.70%. With a float of $117.19 million, this company’s outstanding shares have now reached $167.43 million.
The extent of productivity of a business whose workforce counts for 93 workers is very important to gauge. In terms of profitability, gross margin is 69.97%, operating margin of -3411.51%, and the pretax margin is 489.32%.
X4 Pharmaceuticals Inc (XFOR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of X4 Pharmaceuticals Inc is 30.45%, while institutional ownership is 38.62%. The most recent insider transaction that took place on Oct 15 ’24, was worth 17,926. In this transaction President and CEO of this company sold 31,897 shares at a rate of $0.56, taking the stock ownership to the 1,025,816 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 31,897 for $0.56, making the entire transaction worth $17,862.
X4 Pharmaceuticals Inc (XFOR) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.01 earnings per share (EPS), higher than consensus estimate (set at -0.15) by 0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 80.70% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
Take a look at X4 Pharmaceuticals Inc’s (XFOR) current performance indicators. Last quarter, stock had a quick ratio of 6.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 149.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.09, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
The latest stats from [X4 Pharmaceuticals Inc, XFOR] show that its last 5-days average volume of 1.1 million was inferior to 2.07 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 18.41%. Additionally, its Average True Range was 0.04.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 3.86%, which indicates a significant decrease from 22.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.50% in the past 14 days, which was lower than the 97.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6288, while its 200-day Moving Average is $0.8675. Now, the first resistance to watch is $0.5105. This is followed by the second major resistance level at $0.5236. The third major resistance level sits at $0.5308. If the price goes on to break the first support level at $0.4902, it is likely to go to the next support level at $0.4830. The third support level lies at $0.4699 if the price breaches the second support level.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
The company with the Market Capitalisation of 83.83 million has total of 168,500K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -101,170 K annual income. Company’s last quarter sales were recorded 560 K and last quarter income was 90,830 K.
